In the latest trading session, 0.46 million Apogee Therapeutics Inc. (NASDAQ:APGE) shares changed hands as the company’s beta touched 2.83. With the company’s most recent per share price at $40.07 changing hands around $0.47 or 1.19% at last look, the market valuation stands at $1.49B. APGE’s current price is a discount, trading about -80.41% off its 52-week high of $72.29. The share price had its 52-week low at $14.19, which suggests the last value was 64.59% up since then. When we look at Apogee Therapeutics Inc.’s average trading volume, we note the 3-month average coming to 436.86K.
Apogee Therapeutics Inc. (NASDAQ:APGE) trade information
Instantly APGE is in green as seen in intraday trades today. With action 3.86%, the performance over the past five days has been green. The jump to weekly highs of 40.63 added 1.19% to the stock’s daily price. The company’s shares are showing year-to-date upside of 43.41%, with the 5-day performance at 3.86% in the green. However, in the 30-day time frame, Apogee Therapeutics Inc. (NASDAQ:APGE) is -4.86% down.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Apogee Therapeutics Inc. (APGE) estimates and forecasts
Data shows that the Apogee Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 45.39% over the past 6 months, a 21.43% in annual growth rate that is considerably higher than the industry average of 15.50%.
The 2024 estimates are for Apogee Therapeutics Inc. earnings to increase by 22.77%.
APGE Dividends
Apogee Therapeutics Inc. is expected to release its next quarterly earnings report in August.
